Journal of Clinical Gastroenterology and Hepatology Open Access

  • ISSN: 2575-7733
  • Journal h-index: 5
  • Journal CiteScore: 0.63
  • Journal Impact Factor: 0.41
  • Average acceptance to publication time (5-7 days)
  • Average article processing time (30-45 days) Less than 5 volumes 30 days
    8 - 9 volumes 40 days
    10 and more volumes 45 days
Reach us +32 25889658

GASTRIC BYPASS, AS A METABOLIC TREATMENT IN TYPE 2 DIABETES MELLITUS AND GRADE 1 OBESITY

11th Annual European Conference on Gastroenterology
March 11-12, 2019 | Amsterdam, Netherlands

Luis Menchaca

Autonomous University of Nuevo Leon, Mexico.

Keynote: J Clin Gastroenterol Hepatol

Abstract:

Background: Type 2 diabetes (DM2) is a public health problem worldwide. In 1994, Pories reported glycemia correction after bypass gastric in obese patient with DM2.Then Rubino, Scopinaro (2002) and Carbajo (2008) confirmed this glycemia normalization during the first postoperative week. Studies in patients submitted to gastrojejunal surgery due to peptic acid disease or neoplasms, reported similar results in blood glucose control. The American Diabetes Association justifies under protocol study be performed this procedure in patients with BMI between 30 and 35.

Materials & Methods: This is a non-blind experimental cohort study including 47 patients with type 2 diabetes and Grade 1 obesity at the High Specialty Regional Monterrey Hospital, ISSSTE. Out of them, 13 patients (Cases) underwent gastric bypass and compared with 34 patients (control), in conventional clinical treatment, with one year follow up.

Results: The 13 patients who underwent surgery (eight female and five male), started with a mean HbA1c=9.7% which decreased to 6% post-surgery. Only three of them continue with oral hypoglycemic agents with minimal doses. Regarding the 34 clinical treatment patients, their initial (2015) mean HbA1c=9.2% HbA1c, and their 2016 mean=8.9%, maintaining medications.

Discussion: The control group has a high risk of complications. Gastric bypass showed to be more effective in controlling of HbA1c.

Conclusions: Patients with DM2 and BMI between 30 and 35 are highly vulnerable group, which should be included in bariatric surgical procedures to avoid complications with irreparable damage.

Biography :

Luis Menchaca has completed his PhD at the age of 25 years from Universidad Autónoma de Nuevo León and postdoctoral studies from ISSSTE/ UANL School of Medicine. He is General Surgeon by 28 years, Chief of Educational Department in ISSSTELEON. He has a special interest in educating and mentoring Residents in training and Medical Students. He has published 2 papers in reputed journals one the Utility of Simulators in Laparoscopic Surgery and Research about Metabolic Answer post GBP and several posters and speeches in Mexican Congress of Surgery.

E-mail: luismenchaca56@hotmail.com